Autor según el artículo: Felipe Reyes, Luis; Rodriguez, Alejandro; Bastidas, Alirio; Parra-Tanoux, Daniela; Fuentes, Yuli, V; Garcia-Gallo, Esteban; Moreno, Gerard; Ospina-Tascon, Gustavo; Hernandez, Gleen; Silva, Edwin; Diaz, Ana Maria; Jibaja, Manuel; Vera-Alarcon, Magdalena; Diaz, Emilio; Bodi, Maria; Sole-Violan, Jordi; Ferrer, Ricard; Albaya-Moreno, Antonio; Socias, Lorenzo; Estella, Angel; Loza-Vazquez, Ana; Jorge-Garcia, Ruth; Sancho, Isabel; Martin-Loeches, Ignacio;LIVEN-COVID-19 Investigators; COVID-19 SEMICYUC Study Grp
Departamento: Medicina i Cirurgia
Autor/es de la URV: Bodi Saera, Maria Amparo / Rodríguez Oviedo, Alejandro Hugo
Palabras clave: Ventilator-associated pneumonia Severe covid-19 Prevalence Pneumonia Hospitalized-patients Dexamethasone Critical care Covid-19
Resumen: Purpose: Dexamethasone is the only drug that has consistently reduced mortality in patients with COVID-19, es-pecially in patients needing oxygen or invasive mechanical ventilation. However, there is a growing concern about the relation of dexamethasone with the unprecedented rates of ICU-acquired respiratory tract infections (ICU-RTI) observed in patients with severe COVID-19. Methods: This was a multicenter, prospective cohort study; conducted in ten countries in Latin America and Europe. We included patients older than 18 with confirmed SARS-CoV-2 requiring ICU admission. A multivariate logistic regression and propensity score matching (PSM) analysis was conducted to determine the relation be-tween dexamethasone treatment and ICU-RTI. Results: A total of 3777 patients were included. 2065 (54.7%) were treated with dexamethasone within the first 24 h of admission. After performing the PSM, patients treated with dexamethasone showed significantly higher proportions of VAP (282/1652 [17.1%] Vs. 218/1652 [13.2%], p = 0.014). Also, dexamethasone treatment was identified as an adjusted risk factor of ICU-RTI in the multivariate logistic regression model (OR 1.64; 95%CI: 1.37-1.97; p < 0.001).
Áreas temáticas: Saúde coletiva Nutrição Medicina iii Medicina ii Medicina i Matemática / probabilidade e estatística Interdisciplinar General medicine Engenharias iv Enfermagem Emergency medicine & critical care Educação física Critical care medicine Critical care and intensive care medicine Ciências biológicas ii Ciências biológicas i Ciência de alimentos Astronomia / física
Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
Direcció de correo del autor: alejandrohugo.rodriguez@urv.cat mariaamparo.bodi@urv.cat mariaamparo.bodi@urv.cat
Identificador del autor: 0000-0001-8828-5984 0000-0001-7652-8379 0000-0001-7652-8379
Fecha de alta del registro: 2023-09-02
Versión del articulo depositado: info:eu-repo/semantics/publishedVersion
Enlace a la fuente original: https://www.sciencedirect.com/science/article/pii/S0883944122000405
URL Documento de licencia: http://repositori.urv.cat/ca/proteccio-de-dades/
Referencia al articulo segun fuente origial: Journal Of Critical Care. 69 154014-
Referencia de l'ítem segons les normes APA: Felipe Reyes, Luis; Rodriguez, Alejandro; Bastidas, Alirio; Parra-Tanoux, Daniela; Fuentes, Yuli, V; Garcia-Gallo, Esteban; Moreno, Gerard; Ospina-Tas (2022). Dexamethasone as risk-factor for ICU-acquired respiratory tract infections in severe COVID-19. Journal Of Critical Care, 69(), 154014-. DOI: 10.1016/j.jcrc.2022.154014
DOI del artículo: 10.1016/j.jcrc.2022.154014
Entidad: Universitat Rovira i Virgili
Año de publicación de la revista: 2022
Tipo de publicación: Journal Publications
Repositori URV